Acute lymphoblastic leukaemia trials in Germany

In Germany 35 Also abroad 563

35 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Asciminib Roll-over Study
Where
Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, Wuerzburg
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 1Taking people
A Phase I Dose Finding Study of MB-CART2219.1
Where
Tuebingen
Age
12 years to 75 years
People
36
Run by
University Hospital Tuebingen
See details and how to joinNCT07108868 · EU 2024-516838-35-00
Phase 3Taking people
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Where
Muenster
Age
1 year to 64 years
People
130 worldwide
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT07223021 · EU 2025-523096-34-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Berlin, Cologne, Giessen, Muenster, Tuebingen
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
No phaseTaking people
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
Where
Erlangen
Age
3 years and over
People
180
Run by
University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07705178
Phase 3Taking people
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Where
Berlin
Age
1 year to 64 years
People
750 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Dresden, Frankfurt Am Main, Halle (Saale), Heidelberg, Munich, Ulm
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 2/3Taking people
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Where
Frankfurt
Age
3 months to 25 years
People
1,000 worldwide
Run by
Bambino Gesù Hospital and Research Institute
See details and how to joinNCT07297914 · EU 2025-522052-13-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Aachen, Augsburg, Berlin, Bonn, Bremen, Cologne, Dortmund, Dresden, Duesseldorf, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Halle Saale, Hamburg, Hanover, Heidelberg, Kiel, Krefeld, Mainz, Muenster, Munich, Stuttgart, Tuebingen, Ulm
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Giessen, Mainz
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 1/2Taking people
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Where
Berlin, Cologne, Duesseldorf, Essen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Kiel, Muenster, Munich, Wuerzburg
Age
12 years and over
People
255 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Hamburg, Leipzig, Mainz, Ulm
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1/2Taking people
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Where
Berlin, Cologne, Erlangen, Goettingen, Muenster, Munich, Tuebingen, Wuerzburg
People
40
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT06508775 · EU 2022-501648-14-00
Phase 1/2Not yet taking people in Germany
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
Where
Berlin, Cologne, Erlangen, Essen, Frankfurt Am Main, Hamburg
Age
Up to 64 years
People
22 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522019-40-00 · EU 2025-522019-40-00
Phase 2Taking people
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Where
Berlin, Duesseldorf, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Hamburg, Hanover, Jena, Kiel, Muenster, Tuebingen, Ulm, Wuerzburg
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00
Phase 3Not yet taking people in Germany
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
Where
Aachen, Augsburg, Berlin, Brunswick, Chemnitz, Cologne, Cottbus, Dortmund, Dresden, Duesseldorf, Erfurt, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Goettingen, Greifswald, Halle (Saale), Hanover, Heidelberg, Heilbronn, Herdecke, Homburg, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Leipzig, Luebeck, Magdeburg, Mannheim, Minden, Muenster, Munich, Nuernberg, Oldenburg, Regensburg, Rostock, Sankt Augustin, Schwerin, Stuttgart, Tuebingen, Ulm, Witten, Wolfsburg, Wuerzburg
Age
Up to 17 years
People
2,250
Run by
Universitaetsklinikum Schleswig-Holstein AöR
See details and how to join2025-522190-11-01 · EU 2025-522190-11-01
Phase 2/3Taking people
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Where
Aachen, Berlin, Bonn, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Greifswald, Halle (Saale), Hamburg, Hanover, Heidelberg, Jena, Kiel, Leipzig, Muenster, Munich, Regensburg, Tuebingen, Ulm, Wuerzburg
Age
1 month to 18 years
People
1,800 worldwide
Run by
St. Anna Kinderkrebsforschung
See details and how to joinNCT01949129 · EU 2024-512657-24-00
Phase 2Taking people
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Where
Augsburg, Berlin, Bremen, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Goettingen, Hamburg, Heidelberg, Kiel, Leipzig, Muenster, Munich, Oldenburg, Stuttgart, Ulm
Age
18 years and over
People
28
Run by
Goethe University
See details and how to joinNCT06648889 · EU 2023-507899-47-00
Phase 3Taking people
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Where
Bielefeld, Bonn, Bremen, Hamburg, Krefeld, Mainz
Age
0 years to 45 years
People
6,430 worldwide
Run by
Mats Heyman
See details and how to joinNCT04307576 · EU 2022-501050-11-01
No phaseTaking people
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
Where
Aachen, Altenburg, Altötting, Aschaffenburg, Augsburg, Bad Saarow, Bamberg, Bayreuth, Berlin, Bielefeld, Bochum, Bonn, Braunschweig, Bremen, Chemnitz, Cologne, Cottbus, Darmstadt, Dessau, Dortmund, Dresden, Duisburg, Düren, Düsseldorf, Erfurt, Erlangen, Eschweiler, Essen, Flensburg, Frankfurt, Frankfurt am Main, Freiburg im Breisgau, Fulda, Georgsmarienhütte, Giessen, Goch, Göttingen, Greifswald, Gütersloh, Hagen, Halle, Hamburg, Hamm, Hanover, Heidelberg, Heilbronn, Herne, Hildesheim, Homburg/Saar, Idar-Oberstein, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Krefeld, Kulmbach, Landshut, Leipzig, Lippe, Lübeck, Lüdenscheid, Ludwigshafen, Magdeburg, Mainz, Mannheim, Marburg, Meschede, Minden, Mönchengladbach, München, Münster, Mutlangen, Neubrandenburg, Nordhausen, Nuremberg, Offenburg, Oldenburg, Osnabrück, Paderborn, Passau, Potsdam, Recklinghausen, Regensburg, Reutlingen, Riesa, Rostock, Rotenburg (Wümme), Saarlouis, Sande, Schwäbisch Hall, Schwerin, Siegen, Sindelfingen, Speyer, Stuttgart, Traunstein, Trier, Tübingen, Ulm, Villingen-Schwenningen, Wiesbaden, Winnenden, Wolfsburg, Wuppertal, Würzburg, Zwickau
Age
18 years and over
People
10,000 worldwide
Run by
Goethe University
See details and how to joinNCT02872987
Phase 2Not yet taking people in Germany
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
Where
Frankfurt Am Main
People
86 worldwide
Run by
Centre Hospitalier De Versailles
See details and how to join2024-516570-30-00 · EU 2024-516570-30-00
Phase 1/2Taking people
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia
Where
Berlin, Essen, Frankfurt Am Main, Muenster
Age
Up to 17 years
People
142 worldwide
Run by
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See details and how to join2023-504694-20-00 · EU 2023-504694-20-00
Phase 3Taking people
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
Where
Aachen, Augsburg, Berlin, Bremen, Dortmund, Dresden, Düsseldorf, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Giessen, Hamburg, Hannover, Heidelberg, Homburg, Kiel, Leipzig, Mainz, Münster, Stuttgart, Tübingen, Ulm
Age
Up to 64 years
People
87 worldwide
Run by
Universita Degli Studi Di Milano Bicocca
See details and how to join2025-520982-39-00 · EU 2025-520982-39-00
Phase 3Taking people
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Where
Dresden, Hamburg, Stuttgart
Age
18 years and over
People
350 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06051409 · EU 2024-511496-14-00
Phase 2Taking people
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Where
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Bremen, Brunswick, Cologne, Cottbus, Datteln, Dortmund, Dresden, Duesseldorf, Erfurt, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Goettingen, Greifswald, Halle Saale, Hamburg, Herdecke, Homburg, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Leipzig, Magdeburg, Mainz, Muenster, Munich, Oldenburg, Regensburg, Rostock, Sankt Augustin, Schwerin, Stuttgart, Tuebingen, Ulm, Wuerzburg
Age
Up to 17 years
People
250 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT03590171 · EU 2024-513070-21-00